Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Komet-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed/Refractory Acute Myeloid Leukemia

Aaron D. Goldberg, Daniel Corum, Julie Ahsan, Kun Nie, Tom Kozlek, Mollie Leoni, Stephen Dale

Blood (2023) 142 (Supplement 1): 1553.

https://doi.org/10.1182/blood-2023-190475

Published: 2023

Journal Articles

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Max S. Topp, MD, Zachary F. Zimmerman, MD PhD, Paul Cannell, MD, Herve Dombret, MD, Anthony S. Stein, MD, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong, PhD, Andre Schuh, MD FRCPC

Blood (2017) 130 (Supplement 1): 2571.

https://doi.org/10.1182/blood.V130.Suppl_1.2571.2571

Published: 2017

Journal Articles

Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial

Alessandro Rambaldi, MD Prof, Françoise Rigal-Huguet, MD, Pavel Zak, Paul Cannell, MD, Kun Nie, PhD, Zachary F. Zimmerman, MD PhD, Max S. Topp, MD

Blood (2017) 130 (Supplement 1): 2552.

https://doi.org/10.1182/blood.V130.Suppl_1.2552.2552

Published: 2017

Journal Articles

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Max S Topp, MD, Zachary Zimmerman, MD PhD, Paul Cannell, MD, Hervé Dombret, MD PhD, Johan Maertens, MD PhD, Andre C. Schuh, MD FRCPC, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong

Blood (2016) 128 (22): 222.

https://doi.org/10.1182/blood.V128.22.222.222

Published: 2016

Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Michael D Tarantino, MD, James B. Bussel, Victor S. Blanchette, Jenny Despotovic, Carolyn Bennett, Ashok Raj, MD, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, Nancy Carpenter, Kun Nie, Melissa Eisen

Blood (2015) 126 (23): 7.

https://doi.org/10.1182/blood.V126.23.7.7

Published: 2015

Journal Articles

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

Michael D Tarantino, MD, James B. Bussel, MD, Victor S. Blanchette, MD FRCP, Jenny M. Despotovic, DO, MS, Carolyn Bennett, Ashok Raj, MD, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, DO, Kun Nie, Melissa Eisen, MD

Blood (2015) 126 (23): 3467.

https://doi.org/10.1182/blood.V126.23.3467.3467

Published: 2015

Journal Articles

Safety and Efficacy of Long-Term Open-Label Dosing of Romiplostim in Thrombocytopenic Pediatric Patients (Pts) with Immune Thrombocytopenia (ITP)

James B. Bussel, MD, Michael D. Tarantino, Amy Geddis, Michael F. Guerrera, Alan K. Ikeda, Kun Nie, Janet Franklin, Melissa Eisen

Blood (2014) 124 (21): 4184.

https://doi.org/10.1182/blood.V124.21.4184.4184

Published: 2014

Journal Articles

Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Michael D. Tarantino, MD, James B. Bussel, MD, Amy Geddis, MD, Michael F. Guerrera, MD, Alan K. Ikeda, MD, Kun Nie, PhD, Melissa Eisen, MD

Blood (2013) 122 (21): 3530.

https://doi.org/10.1182/blood.V122.21.3530.3530

Published: 2013

Journal Articles

Long-Term Use of Open-Label Romiplostim in Children with Chronic/Refractory Immune Thrombocytopenia (ITP)

James B Bussel, MD, George R. Buchanan, MD, David J. Gnarra, MD, Richard H. Ho, MD, MSCI, Kun Nie, Melissa Eisen, MD

Blood (2012) 120 (21): 621.

https://doi.org/10.1182/blood.V120.21.621.621

Published: 2012

Journal Articles

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia

James B. Bussel, George R. Buchanan, Diane J. Nugent, David J. Gnarra, Lisa R. Bomgaars, Victor S. Blanchette, Yow-Ming Wang, Kun Nie, Susie Jun

Blood (2011) 118 (1): 28–36.

https://doi.org/10.1182/blood-2010-10-313908

Published: 2011

Journal Articles

Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study

David J. Kuter, MD, DPhil, James B. Bussel, MD, Adrian Newland, FRCP, Jeffrey S. Wasser, MD, Roger M Lyons, MD, James N. George, MD, Gail Macik, MD, Kun Nie, Susie Jun

Blood (2010) 116 (21): 68.

https://doi.org/10.1182/blood.V116.21.68.68

Published: 2010

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).

George R. Buchanan, MD, Lisa Bomgaars, MD, James B. Bussel, MD, Diane J. Nugent, MD, David J. Gnarra, MD, Victor S Blanchette, FRCP, Kun Nie, Melissa Eisen, MD, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 680.

https://doi.org/10.1182/blood.V114.22.680.680

Published: 2009

Journal Articles

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

James B. Bussel, MD, David J Kuter, MD, DPhil, Adrian Newland, MD, FRCP, Joost TM de Wolf, MD, Jeffrey Wasser, MD, Paul Chang, Kun Nie, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 681.

https://doi.org/10.1182/blood.V114.22.681.681

Published: 2009

Journal Articles

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

David J Kuter, MD, DPhil, James B Bussel, MD, Adrian Newland, MD, FRCP, Joost TM de Wolf, MD, Troy Guthrie, MD, Jeffrey Wasser, MD, Lara Gehl, Kun Nie, PhD, Dietmar Berger, MD, PhD

Blood (2008) 112 (11): 402.

https://doi.org/10.1182/blood.V112.11.402.402

Published: 2008

Journal Articles

Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP)

James George, MD, James B Bussel, MD, Roger M Lyons, MD, Vinod Pullarkat, MD, Robert Redner, MD, Deirdra Terrell, PhD, Kun Nie, PhD, Dietmar Berger, MD, PhD

Blood (2008) 112 (11): 4707.

https://doi.org/10.1182/blood.V112.11.4707.4707

Published: 2008

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Interim Results from an Open-Label Study of AMG 531.

Michael D. Tarantino, David H. Henry, Ronald S. Go, Francois Lefrere, Alan E. Lichtin, Howard R. Terebelo, Jean-Francois Viallard, Susan D. Mathias, Robert Deeter, Kun Nie, Janet L. Nichol

Blood (2007) 110 (11): 1324.

https://doi.org/10.1182/blood.V110.11.1324.1324

Published: 2007

NARROW

Komet-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed/Refractory Acute Myeloid Leukemia

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Long-Term Open-Label Dosing of Romiplostim in Thrombocytopenic Pediatric Patients (Pts) with Immune Thrombocytopenia (ITP)

Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Long-Term Use of Open-Label Romiplostim in Children with Chronic/Refractory Immune Thrombocytopenia (ITP)

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia

Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study

A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP)

Health-Related Quality of Life (HRQoL) in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Interim Results from an Open-Label Study of AMG 531.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only